Infectious Vaccine Collaboration, Development, Research and Licensing Deals Trends Report 2024 with Directory of 522 Agreements Signed Since 2019

Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to's offering.

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 522 infectious vaccine deals announced since 2016 including financial terms where available including links to online deal records of actual infectious vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report also includes numerous table and figures that illustrate the trends and activities in infectious vaccine deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Benefits

  • Understand deal trends since 2016
  • Browse infectious vaccine collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in infectious vaccine dealmaking
2.1. Introduction
2.2. Infectious vaccine deals over the years
2.3. Most active infectious vaccine dealmakers
2.4. Infectious vaccine deals by deal type
2.5. Infectious vaccine deals by therapy area
2.6. Infectious vaccine deals by industry sector
2.7. Deal terms for infectious vaccine deals
2.7.1 Infectious vaccine deals headline values
2.7.2 Infectious vaccine deal upfront payments
2.7.3 Infectious vaccine deal milestone payments
2.7.4 Infectious vaccine royalty rates

Chapter 3 - Leading infectious vaccine deals
3.1. Introduction
3.2. Top infectious vaccine deals by value

Chapter 4 - Most active infectious vaccine dealmakers
4.1. Introduction
4.2. Most active infectious vaccine dealmakers
4.3. Most active infectious vaccine deals company profiles

Chapter 5 - Infectious vaccine contracts dealmaking directory
5.1. Introduction
5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 - Infectious vaccine dealmaking by technology type

Deal directory

  • Deal directory - Infectious vaccine deals by company A-Z
  • Deal directory - Infectious vaccine deals by deal type
  • Deal directory - Infectious vaccine deals by therapy area
  • Deal type definitions

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.